Onconetix, Inc.

What they do

Onconetix owns Proclarix, an in vitro diagnostic test for prostate cancer developed by Proteomedix, acquired in December 2023, and approved for sale in the EU under IVDR. Proclarix is a protein-based blood test used on the same sample as a PSA test, aimed at the diagnostic 'grey zone' where PSA results are unclear. The company relies on third-party single-source manufacturers and expects U.S. marketing as a lab developed test through a license agreement with LabCorp. It abandoned commercialization of ENTADFI, an FDA-approved finasteride/tadalafil BPH pill, and no longer holds inventory as of December 31, 2025.

Revenue drivers

• Proclarix (Europe) — CE-marked prostate cancer diagnostic sold in the European Union and, per the 10-Q, now offered in the UK by a patient organization in a screening initiative; this is the company's only active product.
• Proclarix (U.S. planned) — Anticipated to be marketed in the U.S. as a lab developed test through the LabCorp license agreement; no U.S. revenue is reported in the provided filings.
• ENTADFI (discontinued) — FDA-approved BPH pill whose commercialization was abandoned; inventory no longer held as of December 31, 2025, and ENTADFI assets were fully impaired at June 30, 2024.

Recent performance

Annual revenue was $2.5 million in 2024 and $815,371 in 2025, down sharply year over year. Quarterly revenue fell from $303,651 in the quarter ended September 30, 2025 to $303,596 in the quarter ended December 31, 2025, then to $21,457 in the quarter ended March 31, 2026 and $17,120 in the quarter ended June 30, 2026. Net loss was $58.7 million in 2024 and $14.0 million in 2025, with accumulated deficit of $131.2 million at December 31, 2025. Operating cash flow was negative $9.7 million in 2025. At June 30, 2026, total assets were $16.4 million, total liabilities $3.0 million, shareholder equity $13.5 million, and cash and equivalents $5.9 million.

Strategy

The company is focusing its efforts on commercializing Proclarix and expects growing revenues from Proclarix sales in 2026 and beyond. It anticipates those sales will offset some expenses relating to commercial scale up and development, while total expenses are also expected to increase for commercialization, additional hires, public company costs, intellectual property, and product validation studies under the LabCorp license agreement. Cost reduction actions have included terminating three ENTADFI-program employees effective April 30, 2024, and abandoning ENTADFI. Manufacturing remains outsourced, with main suppliers being single-source. The company has also entered into a Share Exchange Agreement with Realbotix, LLC, referenced in its forward-looking statements.

Risks

• Going concern and funding need — The 10-K states there is substantial doubt about the company's ability to continue as a going concern and that it will require substantial additional funding for long-term operations.
• Minimal and declining revenue — Revenue fell from $2.5 million in 2024 to $815,371 in 2025, with quarterly revenue only $21,457 and $17,120 in the first two quarters of 2026.
• Single-product concentration — Proclarix is the only product approved for sale, and ENTADFI commercialization was abandoned with inventory destroyed, leaving no fallback revenue.
• Third-party and single-source dependence — The company has no internal manufacturing capabilities and relies on third parties, with main suppliers being single-source, for commercial product.

Outlook

Management says it continues sales efforts and expects growing revenues from Proclarix in 2026 and beyond, while expecting expenses to increase with commercial scale up and development. It cites two peer-reviewed Proclarix publications in the first quarter of 2026: a 371-man cohort study in BMC Cancer and a 132-man active surveillance study in Cancers. The company also references the Realbotix share exchange transaction in its forward-looking statements. The 10-K reiterates substantial doubt about going concern absent additional capital.